(Q46978352)

27 December 2017

title

Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex (English)

1 reference

27 December 2017

author name string

Mei Huang

1

1 reference

27 December 2017

Junji Ichiwaka

2

1 reference

27 December 2017

Zhu Li

3

1 reference

27 December 2017

Jin Dai

4

1 reference

27 December 2017

Herbert Y Meltzer

5

1 reference

27 December 2017

publication date

7 March 2006

1 reference

27 December 2017

published in

Psychopharmacology

1 reference

27 December 2017

volume

185

1 reference

27 December 2017

issue

3

1 reference

27 December 2017

page(s)

274-281

1 reference

27 December 2017

https://scigraph.springernature.com/pub.10.1007/s00213-005-0206-1

exact match

0 references

cites work

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-005-0206-1

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

21 January 2018

1 reference

12 December 2020

Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons

1 reference

12 December 2020

Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men

1 reference

12 December 2020

Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression

1 reference

12 December 2020

A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence.

1 reference

12 December 2020

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

12 December 2020

Augmentation and combination strategies in treatment-resistant depression.

1 reference

12 December 2020

Depression: a case of neuronal life and death?

1 reference

12 December 2020

Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex

1 reference

12 December 2020

Augmentation of milnacipran by risperidone in treatment for major depression.

1 reference

12 December 2020

Definition and epidemiology of treatment-resistant depression

1 reference

12 December 2020

Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals

1 reference

12 December 2020

Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study

1 reference

12 December 2020

Depression: perspectives from affective neuroscience.

1 reference

12 December 2020

A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression

1 reference

12 December 2020

Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex

1 reference

12 December 2020

DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release

1 reference

12 December 2020

Role of serotonin in depression

1 reference

12 December 2020

Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism.

1 reference

12 December 2020

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

1 reference

12 December 2020

Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens

1 reference

12 December 2020

R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study

1 reference

12 December 2020

Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.

1 reference

12 December 2020

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

1 reference

12 December 2020

Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization.

1 reference

12 December 2020

Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex

1 reference

12 December 2020

The use of antidepressants in novel combination therapies

1 reference

12 December 2020

R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum

1 reference

12 December 2020

Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine

1 reference

12 December 2020

Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

1 reference

12 December 2020

Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram

1 reference

12 December 2020

Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus.

1 reference

12 December 2020

Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.

1 reference

12 December 2020

Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?

1 reference

12 December 2020

S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine

1 reference

12 December 2020

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

12 December 2020

An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.

1 reference

12 December 2020

Effect of acute treatment with YM992 on extracellular serotonin levels in the rat frontal cortex

1 reference

12 December 2020

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

12 December 2020

Histamine regulates food intake through modulating noradrenaline release in the para-ventricular nucleus.

1 reference

12 December 2020

Tranylcypromine plus risperidone for treatment-refractory major depression

1 reference

12 December 2020

Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex

1 reference

12 December 2020

Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study

1 reference

12 December 2020

Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity

1 reference

12 December 2020

Central monoamines and their role in major depression

1 reference

12 December 2020

Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of alpha 2 and 5-HT1A receptors

1 reference

12 December 2020

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

12 December 2020

Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial

1 reference

12 December 2020

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat.

1 reference

12 December 2020

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

12 December 2020

What role do atypical antipsychotic drugs have in treatment-resistant depression?

1 reference

12 December 2020

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

1 reference

12 December 2020

Influence of 5-HT1A receptors on central noradrenergic activity: microdialysis studies using (+/-)-MDL 73005EF and its enantiomers.

1 reference

12 December 2020

In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine

1 reference

12 December 2020

New approaches to the treatment of depression

1 reference

12 December 2020

Treatment of major depression: is improvement enough?

1 reference

12 December 2020

Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement

1 reference

12 December 2020

Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its a

1 reference

12 December 2020

A novel augmentation strategy for treating resistant major depression

1 reference

12 December 2020

1 reference

12 December 2020

Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex

1 reference

12 December 2020

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

1 reference

12 December 2020

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

1 reference

12 December 2020

Are atypical antipsychotic drugs also atypical antidepressants?

1 reference

12 December 2020

Depression and antidepressant therapy: receptor dynamics

1 reference

12 December 2020

Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats.

1 reference

12 December 2020

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.

1 reference

12 December 2020

Treatment algorithms in treatment-resistant depression

1 reference

12 December 2020

Treatment options for refractory depression

1 reference

12 December 2020

The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder

1 reference

12 December 2020

Selective reduction by isolation rearing of 5-HT1A receptor-mediated dopamine release in vivo in the frontal cortex of mice

1 reference

12 December 2020

10.1007/S00213-005-0206-1

Identifiers

DOI

1 reference

27 December 2017

PubMed ID

16521036

1 reference

27 December 2017